Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nathalie Ausias"'
Autor:
Heloise Capelle, Joelle Birnbaum, Pascale Tomasini, Céline Tummino, Marion Gouitaa, Nathalie Ausias, Denis Charpin, Fabrice Barlesi, Marc Montana
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 17, Iss 2 (2014)
Pemetrexed is approved to treat non-small cell lung cancer and has an overall favorable toxicity profile. We describe a 58-year-old man who developped an anaphylactic shock within few minutes from the beginning of pemetrexed perfusion. Pemetrexed was
Externí odkaz:
https://doaj.org/article/ab7f921a790d4d6993bb4ae494607f4e
Autor:
Nathalie Ausias, Patrice Vanelle, Fabrice Barlesi, Roch Giorgi, Marc Montana, Mathieu Peretti, Marie Eve Garcia, François Cavaille
Publikováno v:
Tumori
Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩
Tumori, Casa Editrice Ambrosiana, 2020, pp.030089162092624. ⟨10.1177/0300891620926244⟩
Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩
Tumori, Casa Editrice Ambrosiana, 2020, pp.030089162092624. ⟨10.1177/0300891620926244⟩
Background: Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. Aim: To inve
Autor:
Patrice Vanelle, Marc Montana, Fabrice Barlesi, Nathalie Ausias, Marie-Eve Garcia, Marion Jeanpierre, Margaux Meiffren, Roch Giorgi
Publikováno v:
Journal of chemotherapy (Florence, Italy)
Journal of chemotherapy (Florence, Italy), 2018, pp.1--5. ⟨10.1080/1120009X.2018.1551753⟩
Journal of chemotherapy (Florence, Italy), 2018, pp.1--5. ⟨10.1080/1120009X.2018.1551753⟩
MEDLINE:30595104; Nivolumab, a fully human immunoglobulin monoclonal antibody inhibiting the programmed cell death protein-1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. The ai
Autor:
Pascale Tomasini, Fabrice Barlesi, Heloise Capelle, Marc Montana, Denis Charpin, Nathalie Ausias, Joëlle Birnbaum, Céline Tummino, Marion Gouitaa
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 17, Iss 2 (2014)
Pemetrexed is approved to treat non-small cell lung cancer and has an overall favorable toxicity profile. We describe a 58-year-old man who developped an anaphylactic shock within few minutes from the beginning of pemetrexed perfusion. Pemetrexed was